Pioneering for patients

In the spotlight

We are Galapagos

Galapagos is a fully integrated biotechnology company focused on discovering, developing and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 3 programs in inflammation, oncology, fibrosis, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in the European Union, Norway, the United Kingdom, and Japan.

Learn more about Galapagos

News

Loading...

All Galapagos news

Events

Loading...

All Galapagos events

Job Openings

Loading...

All Current Openings